The invention provides methods for using F16 isoindole small molecules for treatment of solid tumors, particularly brain cancers, such as glioblastoma multiforme (GBM). F16 isoindole is an inhibitor of angiogenesis and is capable of antagonizing tumor vasculature. The invention also provides pharmaceutical compositions including F16 isoindole small molecules.

The invention provides methods for using F16 isoindole small molecules for treatment of solid tumors, particularly brain cancers, such as glioblastoma multiforme (GBM). F16 isoindole is an inhibitor of angiogenesis and is capable of antagonizing tumor vasculature. The invention also provides pharmaceutical compositions including F16 isoindole small molecules.

The present invention provides a low dose topical composition of Apremilast with pharmaceutically acceptable excipients. The present invention also relates to a topical clear gel composition of apremilast for delivering a desired therapeutic amount of drug to the site of action after topical application. The present invention also provides a process for preparation process for preparation of low dose apremilast topical composition with enhanced diffusion and dose-proportionate linear drug release from the composition.

The present invention provides a low dose topical composition of Apremilast with pharmaceutically acceptable excipients. The present invention also relates to a topical clear gel composition of apremilast for delivering a desired therapeutic amount of drug to the site of action after topical application. The present invention also provides a process for preparation process for preparation of low dose apremilast topical composition with enhanced diffusion and dose-proportionate linear drug release from the composition.

Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate are also disclosed.

Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate are also disclosed.

Disclosed are potent immuno-DASH inhibitors and their use in the treatment of cell proliferative diseases.

Disclosed are potent immuno-DASH inhibitors and their use in the treatment of cell proliferative diseases.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.